Complete and print.

Reset Form

MAYO CLINIC LABORATORIES

# Hematopathology/Cytogenetics Test Request*

## Client Information (required)

| | | |
|---|---|---|
| Client Name | | |
| Client Account No. | | |
| Client Phone | Client Order No. | |
| Street Address | | |
| City | State | ZIP Code |

## Submitting Healthcare Professional Information (required)

| |
|---|
| Submitting/Referring Healthcare Professional Name (Last, First) |

**Fill in only if Call Back is required.**

| | |
|---|---|
| Phone (with area code) | Fax* (with area code) |
| National Provider Identification (NPI) | |

***Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

## Pathology/Clinical (required)

| **Include pathology report.** | | |
|---|---|---|
| Include a reason for testing, suspected diagnosis, brief history, and pertinent laboratory results. | | |
| Bone Marrow Transplant<br>☐ Autologous | ☐ Allogeneic | ☐ Sex mis-match |
| Disease Stage<br>☐ New diagnosis | ☐ Relapse | ☐ MRD |
| ICD-10 Diagnosis Code | | |

* If patient is enrolled in the Children's Oncology Group, see Children's Oncology Group Test Request (MC0767-20) to order testing.

## Patient Information (required)

| | |
|---|---|
| Patient ID (Medical Record No.) | |
| Patient Name (Last, First Middle) | |
| Sex<br>☐ Male ☐ Female | Birth Date (mm-dd-yyyy) |
| Collection Date (mm-dd-yyyy) | Time ☐ am ☐ pm |

## Specimens Provided (required)

| | | |
|---|---|---|
| ☐ Blood<br>☐ Bone marrow<br>☐ Fixed cells<br>☐ Cultured cells<br>☐ DNA<br>☐ Lymph node<br>☐ Spleen | ☐ Paraffin block<br>No. sent:<br>Indicate source:<br><br>☐ Slides<br>No. sent: | ☐ Tissue<br>No. sent:<br>☐ Frozen<br>☐ Fixed formalin<br>☐ Wet tissue<br>☐ Other fixative, type:<br><br>☐ Other, anatomic site: |

| CBC Results | | |
|---|---|---|
| HGB | MCV | WBC |
| RBC | RDW | PLT |

## Pathologist Information (required)

| | |
|---|---|
| Submitting/Referring Pathologist Name (Last, First) | |
| Phone (with area code) | Fax** (with area code) |

***Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

**MCL Internal Use Only**

**Note:** It is the client's responsibility to maintain documentation of the order.

**Ship specimens to:**
Mayo Clinic Laboratories
3050 Superior Drive NW
Rochester, MN 55905

**Customer Service: 800-533-1710**

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

**Billing Information**
- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing-related questions:
800-447-6424 (US and Canada)
507-266-5490 (outside the US)





T726
MC0767-05Arev0425

## Patient Information (required)

| | |
|---|---|
| Patient ID (Medical Record No.) | Client Account No. |
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

### Hematopathology Consultation

- ☐ PATHC — Pathology Consultation (submit PB and bone marrow aspirate slides, block)
- ☐ HPWET — Hematopathology Consultation, MCL Embed (submit core biopsy, clot section, bone marrow aspirate and PB slides)
- ☐ HPCUT — Hematopathology Consultation, Client Embed (submit bone marrow liquid aspirate, PB and bone marrow slides and embedded core biopsy and clot section)

**Note: HPWET and HPCUT require MCL approval prior to ordering and submission of specimens.**
Call 800-533-1710 for approval.

### Hematologic Disorders Hold Service

- ☐ HOLDC — Chromosome Hold
- ☐ HOLDF — Fluorescence In Situ Hybridization (FISH) Hold
- ☐ HLLFH — Leukemia/Lymphoma Flow Hold***
- ☐ EXHD — DNA Extract and Hold
- ☐ EXHR — DNA and RNA Extract and Hold

### Flow Cytometry

Leukemia/Lymphoma Immunophenotyping

- ☐ LCMS — Blood/Bone Marrow***
- ☐ LLTOF — Blood/Bone Marrow, Technical Only
- ☐ LLPT — Tissue (with interpretation)
- ☐ LLTOT — Tissue, Technical Only
- ☐ MYEFL — Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow
- ☐ PLINK — Paroxysmal Nocturnal Hemoglobinuria, PI-Linked Antigen, Blood
- ☐ SZDIA — Sezary Diagnostic Flow Cytometry, Blood
- ☐ SZMON — Sezary Monitoring Flow Cytometry, Blood
- ☐ CEE20 — CD20 Cell Expression Evaluation
- ☐ CEE49 — CD49d Cell Expression Evaluation
- ☐ CEE52 — CD52 Cell Expression Evaluation

### Chromosome Analysis

- ☐ CHRBM — Hematologic Disorders, Bone Marrow
- ☐ CHRHB — Hematologic Disorders, Blood

### Next-Generation Sequencing (NGS)

- ☐ NGAML — MayoComplete Acute Myeloid Leukemia, 11-Gene Panel
- ☐ NGAMT — MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), NGS
- ☐ NGBCL — MayoComplete B-Cell Lymphoma, NGS
- ☐ NGCLN — MayoComplete Chronic Lymphoid Neoplasms, NGS
- ☐ NGHIS — MayoComplete Histiocytic Neoplasms, NGS
- ☐ NGSHM — MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing
- ☐ NGPCM — MayoComplete Plasma Cell Myeloma, NGS
- ☐ NGSFX — Reanalysis, AML 4 or 11 Gene Panel,Additional Genes
- ☐ NGTCL — MayoComplete T-Cell Lymphoma, NGS

### Chromosomal Microarray

- ☐ CMAH — Hematologic Disorders

## ACUTE MYELOID LEUKEMIA (AML)/ MYELODYSPLASTIC SYNDROME (MDS)

### Acute Myeloid Leukemia (AML)

- ☐ FLT — FLT3 Mutation Analysis
- ☐ IDHQ — IDH1 (R132) and IDH2 (R140 and R172) Quantitative Detection, Droplet Digital PCR
- ☐ IN16Q — CBFB-MYH11 Inversion(16), Quantitative Detection and Minimal Disease Risk Monitoring, qRT-PCR
- ☐ NGAML — MayoComplete Acute Myeloid Leukemia, 11-Gene Panel
- ☐ NGAMT — MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing
- ☐ NPM1Q — Nucleophosmin (NPM1) Mutation Analysis
- ☐ NGSHM — MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing
- ☐ PMLR — PML/RARA Quantitative, PCR
- ☐ T821Q — RUNX1-RUNX1T1 Translocation (8;21), Minimal Residual Disease Monitoring, Quantitative
- ☐ AMLAF — Acute Myeloid Leukemia (AML), FISH, Adult
- ☐ AMLPF — Acute Myeloid Leukemia (AML), FISH, Pediatric
- ☐ AMLMF — Acute Myeloid Leukemia (AML), Specified FISH

For AMLMF: must specify probe sets to be performed.

- ☐ RUNX1T1/RUNX1 — t(8;21)(q22;q22)
- ☐ MECOM/RUNX1 — t(3;21)(q26.2;q22)
- ☐ PML/RARA — t(15;17)(q24.1;q21.2)
- ☐ RARA/BAP — 17q21 rearrangement
- ☐ MLL (KMT2A) BAP — 11q23 rearrangement
- ☐ AFF1/MLL — t(4;11)(q21;q23)
- ☐ MLLT4/MLL — t(6;11)(q27;q23)
- ☐ MLLT3/MLL — t(9;11)(p22;q23)
- ☐ MLLT10/MLL — t(10;11)(p13;q23)
- ☐ MLL/CREBBP — t(11;16)(q23;p13.3)
- ☐ MLL/MLLT1 — t(11;19)(q23;p13.3)
- ☐ MLL/ELL — t(11;19)(q23;p13.1)
- ☐ MYH11/CBFB — inv(16)(p13q22) or t(16;16)
- ☐ CBFB BAP — 16q22 rearrangement
- ☐ GLIS2/CBFA2T3 — inv(16)
- ☐ NUP98 BAP — 11p15.4 rearrangement
- ☐ HOXA9/NUP98 — t(7;11)(p15;p15.4)
- ☐ ETV6 BAP — 12p13 rearrangement
- ☐ MNX1/ETV6 — t(7;12)(q36;p13)
- ☐ DEK/NUP214 — t(6;9)(p23;q34)
- ☐ RPN1/MECOM — inv(3)(q21.3q26.2) or t(3;3)
- ☐ PRDM16/RPN1 — t(1;3)(p36.3;q21.3)
- ☐ KAT6A/CREBBP — t(8;16)(p11.2;p13.3)
- ☐ RBM15/MKL1 — t(1;22)(p13.3;q13.1)
- ☐ D5S630/EGR1 — -5/5q deletion
- ☐ D7Z1/D7S486 — -7/7q deletion
- ☐ TP53/D17Z1 — -17/17p deletion
- ☐ BCR/ABL1 — t(9;22)(q34;q11.2)
- ☐ ABL1 BAP — 9q34 rearrangement

### Myelodysplasia Syndromes (MDS)

- ☐ MDSDF — Myelodysplastic Syndrome (MDS), Diagnostic FISH
- ☐ MDSMF — Myelodysplastic Syndrome (MDS), Specified FISH

For MDSMF: **must** specify probe sets to be performed.

- ☐ RPN1/MECOM — inv(3)(q21.3q26.2) or t(3;3)
- ☐ PRDM16/RPN1 — t(1;3)(p36.3;q21.3)
- ☐ MECOM/RUNX1 — t(3;21)(q26.2;q22)
- ☐ D5S630/EGR1 — -5/5q deletion
- ☐ D7Z1/D7S486 — -7/7q deletion
- ☐ D8Z2/MYC — +8
- ☐ TP53/D17Z1 — -17/17p deletion
- ☐ D20S108/20qter — -20/20q deletion
- ☐ MYEFL — Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow
- ☐ PLINK — PNH, PI-Linked Antigen, Blood
- ☐ MSTF — Myeloid Sarcoma, FISH, Tissue

Must select probes listed below or entire panel.

- ☐ RUNX1T1/RUNX1 — t(8;21)(q22;q22)
- ☐ BCR/ABL1 — t(9;22)(q34;q11.2)
- ☐ MLL (KMT2A) BAP — 11q23 rearrangement
- ☐ PML/RARA — t(15;17)(q24.1;q21.2)
- ☐ MYH11/CBFB — inv(16)(p13q22) or t(16;16)
- ☐ **Perform entire panel**
- ☐ UBA1Q — UBA1 Mutation Quantitative Detection, VEXAS syndrome, Droplet Digital PCR

*** Algorithms are available online for these tests.
Visit www.MayoClinicLabs.com

## Patient Information (required)

| | |
|---|---|
| Patient ID (Medical Record No.) | Client Account No. |
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

### BONE MARROW TRANSPLANT

| | | |
|---|---|---|
| ☐ | BALLM | B-Cell Lymphoblastic Leukemia Monitoring, Minimal Residual Disease Detection, Flow Cytometry |
| ☐ | CHIDB | Chimerism-Donor |
| ☐ | CHRGB | Chimerism-Recipient Germline (Pretransplant) |
| ☐ | CHIMU | Chimerism Transplant No Cell Sort |
| ☐ | CHIMS | Chimerism Transplant Sorted Cells |
| ☐ | CLLMD | CLL Monitoring, MRD Detection |
| ☐ | 1DIS | HLA A-B-C Disease Association Typing Low Resolution, Blood |
| ☐ | 2DIS | HLA-DR-DQ Disease Association Typing Low Resolution, Blood |

### LYMPHOID DISORDERS

#### B Cell

| | | |
|---|---|---|
| ☐ | BALLM | B-Cell Lymphoblastic Leukemia Monitoring, Minimal Residual Disease Detection, Flow Cytometry |

Immunoglobulin Gene Rearrangement

| | | |
|---|---|---|
| ☐ | BCGR | Blood |
| ☐ | BCGBM | Bone Marrow |
| ☐ | BCGRV | Varies |
| ☐ | NGBCL | MayoComplete B-Cell Lymphoma, Next-Generation Sequencing |
| ☐ | NGCLN | MayoComplete Chronic Lymphoid Neoplasms, Next-Generation Sequencing |
| ☐ | MYD88 | MYD88, L265P, Somatic Gene Mutation, DNA Allele-Specific PCR |
| ☐ | CXLPL | CXCR4 Mutation Analysis, Somatic, Lymphoplasmacytic Lymphoma/ Waldenstrom Macroglobulinemia |
| ☐ | LPLFX | Lymphoplasmacytic Lymphoma/ Waldenstrom Macroglobulinemia (LPL/WM), MYD88 L265P with Reflex to CXCR4 |
| ☐ | SVISC | Viscosity, Serum |
| ☐ | BLBLF | B-Cell Lymphoblastic Leukemia/ Lymphoma, FISH, Tissue |

For BLBLF: **must** specify probe sets to be performed.

| | | |
|---|---|---|
| ☐ | CDKN2A/D9Z1 | +9/9p- |
| ☐ | MLL (KMT2A) break-apart | 11q23 rearrangement |
| ☐ | TP53/D17Z1 | -17/17p- |
| ☐ | PBX1/TCF3 | t(1;19)(q23;p13) |
| ☐ | D4Z1/D10Z1/D17Z1 | Hyperdiploidy, +4,+10,+17 |
| ☐ | ETV6/RUNX1 fusion and iAMP21 | t(12;21)(p13;q22) |
| ☐ | IGH break-apart | 14q32 rearrangement |
| ☐ | MYC break-apart | 8q24.1 rearrangement |

☐ **Perform entire panel**

| | | |
|---|---|---|
| ☐ | PHLDF | Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL), Diagnostic FISH |
| ☐ | BALAF | B-Cell Acute Lymphoblastic Leukemia/ Lymphoma (ALL), FISH, Adult |
| ☐ | BALPF | B-Cell Acute Lymphoblastic Leukemia/ Lymphoma (ALL), Pediatric, FISH |
| ☐ | BALMF | B-Cell Acute Lymphoblastic Leukemia/ Lymphoma (ALL), Specified FISH |

For BALMF: **must** specify probe sets to be performed.

| | | |
|---|---|---|
| ☐ | ABL2 break-apart | 1q25 rearrangement |
| ☐ | PDGFRB break-apart | 5q32 rearrangement |
| ☐ | IKZF1/CEP7 | 7p- |
| ☐ | JAK2 break-apart | 9p24.1 rearrangement |
| ☐ | CDKN2A/D9Z1 | +9/9p- |
| ☐ | BCR/ABL1 | t(9;22) |
| ☐ | ABL1 break-apart | 9q34 rearrangement |
| ☐ | MLL (KMT2A) break-apart | 11q23 rearrangement |
| ☐ | AFF1/MLL | t(4;11)(q21;q23) |
| ☐ | MLLT4(AFDN)/MLL | t(6;11)(q27;q23) |
| ☐ | MLLT3/MLL | t(9;11)(p21;q23) |
| ☐ | MLLT10/MLL | t(10;11)(p13;q23) |
| ☐ | MLL/ELL | t(11;19)(q23;p13.1) |
| ☐ | MLL/MLLT1 | t(11;19)(q23;p13.3) |
| ☐ | TP53/D17Z1 | -17/17p- |
| ☐ | PBX1/TCF3 | t(1;19)(q23;p13) |
| ☐ | D4Z1/D10Z1/D17Z1 | +4,+10,+17, Hyperdiploidy |
| ☐ | ETV6/RUNX1 & iAMP21 | t(12;21)(p13;q22) |
| ☐ | ETV6 break-apart | 12p13 rearrangement |
| ☐ | IGH break-apart | 14q32 rearrangement |
| ☐ | P2RY8 rearrangement | t(Xp22.33;var) or t(Yp11.32;var) |
| ☐ | CRLF2 rearrangement | t(Xp22.33;var) or t(Yp11.32;var) |
| ☐ | CRLF2/IGH | t(X;14)(p22.33;q32) or t(Y;14)(p11.32;q32) |
| ☐ | MYC break-apart | 8q24.1 rearrangement |

| | | |
|---|---|---|
| ☐ | BLPMF | B-Cell Lymphoma, Specified FISH |

For BLPMF: must specify probe sets to be performed. If not specified, probes tested will be determined based on reason for testing.

| | | |
|---|---|---|
| ☐ | MYC break-apart | 8q24.1 rearrangement |
| ☐ | IGK/MYC fusion | t(2;8)(p12;q24.1) |
| ☐ | MYC/IGH fusion | t(8;14)(q24.1;q32) |
| ☐ | MYC/IGL fusion | t(8;22)(q24.1;q11.2) |
| ☐ | BCL6 break-apart | t(3q27;var) rearrangement |
| ☐ | BCL2 break-apart | t(18q21;var) rearrangement |
| ☐ | CCND1/IGH fusion | t(11;14)(q13;q32) |
| ☐ | TP53/D17Z1 | -17/17p- |
| ☐ | D7Z1/7q32 | 7q- |

| | | |
|---|---|---|
| ☐ | BLYM | B-Cell Lymphoma, FISH, Tissue |

*Must select lymphoma subtype.*

#### Burkitt (Pediatric)

Must select probes listed below or entire panel.

| | | |
|---|---|---|
| ☐ | MYC BAP | 8q24.1 rearrangement |
| ☐ | IGK/MYC | t(2;8)(p12;q24.1) |
| ☐ | MYC/IGH | t(8;14)(q24.1;q32) |
| ☐ | MYC/IGL | t(8;22)(q24.1;q11.2) |
| ☐ | BCL6 BAP | 3q27 rearrangement |
| ☐ | BCL2 BAP | 18q21 rearrangement |

☐ **Perform entire Burkitt panel**

#### Diffuse Large B-Cell, Burkitt-Like "Double-Hit"

Must select probes listed below or entire panel.

| | | |
|---|---|---|
| ☐ | MYC BAP | 8q24.1 rearrangement |
| ☐ | MYC/IGH | t(8;14)(q24.1;q32) |
| ☐ | reflex: IGK/MYC | t(2;8)(p12;q24.1) |
| ☐ | reflex: MYC/IGL | t(8;22)(q24.1;q11.2) |
| ☐ | reflex: BCL6 BAP | 3q27 rearrangement |
| ☐ | reflex: BCL2 BAP | 18q21 rearrangement |

☐ **Perform entire frontline "Double-Hit" panel**

#### Follicular

Must select probes listed below or entire panel.

| | | |
|---|---|---|
| ☐ | BCL2 BAP | 18q21 rearrangement |
| ☐ | BCL6 BAP | 3q27 rearrangement |
| ☐ | TNFRSF14/1q22 | deletion of 1p36 |

☐ **Perform entire follicular panel**

#### Histiocytic

| | | |
|---|---|---|
| ☐ | NGHIS | MayoComplete Histiocytic Neoplasms, Next-Generation Sequencing |

#### Mantle Cell

| | | |
|---|---|---|
| ☐ | CCND1/IGH | t(11;14)(q13;q32) |
| ☐ | CCND1 BAP | 11q13 rearrangement |
| ☐ | TP53/D17Z1 | Blastoid subtype only: deletion of 17p |
| ☐ | MYC BAP | Blastoid subtype only: 8q24.1 rearrangement |
| ☐ | CCND2 BAP | Cyclin D1-negative subtype only: 12p13.32 rearrangement |

☐ **Perform entire frontline Mantle Cell panel**

*** Algorithms are available online for these tests.
Visit www.MayoClinicLabs.com

## Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|---|---|
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

### Splenic Marginal Zone Lymphoma (SMZL)

Must select probes listed below or entire panel.

- ☐ D7Z1/7q32 — deletion 7q
- ☐ TP53/D17Z1 — deletion 17p
- ☐ **Perform entire SMZL panel**

### Mucosa-Associated Lymphoid Tissue (MALT/ENMZL) (BLYM only)

- ☐ MALT1 BAP — 18q21 rearrangement

### Large B-Cell with IRF4 Rearrangement (BLYM only)

Must select probes listed below or entire panel.

- ☐ IRF4 BAP — 6p24.3 rearrangement
- ☐ BCL2 BAP — 18q21 rearrangement
- ☐ BCL6 BAP — 3q27 rearrangement
- ☐ **Perform entire Large B-Cell panel**

### Chronic Lymphocytic Leukemia (CLL)

- ☐ CLLMD — Chronic Lymphocytic Leukemia (CLL) Monitoring Minimal Residual Disease (MRD) Detection, Flow Cytometry
- ☐ BCLL — IGH Somatic Hypermutation Analysis, B-Cell (B-CLL)
- ☐ P53CA — Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9
- ☐ CLLDF — Chronic Lymphocytic Leukemia, Diagnostic FISH
- ☐ CLLMF — Chronic Lymphocytic Leukemia, Specified FISH
- ☐ SLL — Small Lymphocytic Lymphoma, FISH, Tissue

For CLLMF, **must** specify probe sets to be performed. For SLL, **must** select **either** individual probes listed below or entire panel

- ☐ D6Z1/MYB — -6/6q deletion
- ☐ D11Z1/ATM — -11/11q deletion
- ☐ D12Z3/MDM2 — +12
- ☐ D13S319/LAMP1 — -13/13q deletion
- ☐ TP53/D17Z1 — -17/17p deletion
- ☐ CCND1/IGH — t(11;14)(q13;q32)
- ☐ IGH/BCL3 — t(14;19)(q32;q13)
- ☐ **Perform entire panel**

- ☐ TLPDF — T-Cell Lymphoma, Diagnostic FISH
- ☐ TLPMF — T-Cell Lymphoma, Specified FISH

For TLPMF: **must** specify probe sets to be performed.

- ☐ TCL1A BAP/TRAD — 14q32.1/14q11.2 rearrangement
- ☐ D7Z1/D7S486 — i(7q)
- ☐ D8Z2/MYC — +8
- ☐ TLYM — T-Cell Lymphoma, FISH, Tissue

Must select probes listed or entire panel.

- ☐ TCL1A BAP/TRAD — 14q32.1/14q11.2 rearrangement
- ☐ D7Z1/D7S486 — -7/iso(7q)
- ☐ D8Z2/MYC — +8
- ☐ ALK BAP — 2p23 rearrangement
- ☐ TP63 BAP — 3q28 rearrangement
- ☐ IRF4 (DUSP22) BAP — 6p25.3 rearrangement
- ☐ **Perform entire panel**

### Congenital Infantile Leukemia

- ☐ CILPF — Congenital Infantile Leukemia, FISH

### T Cell

- ☐ NGTCL — MayoComplete T-Cell Lymphoma, Next-Generation Sequencing

T-Cell Receptor Gene Rearrangement

- ☐ TCGR — PCR, Blood
- ☐ TCGBM — Bone Marrow***
- ☐ TCGRV — Varies
- ☐ SZDIA — Sezary Diagnostic Flow Cytometry, Blood
- ☐ SZMON — Sezary Monitoring Flow Cytometry, Blood
- ☐ TALAF — T-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult
- ☐ TALPF — T-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Pediatric
- ☐ TALMF — T-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH

For TALMF: **must** specify probe sets to be performed.

- ☐ TAL1/STIL — 1p32 rearrangement
- ☐ TLX3/BCL11B — t(5;14)
- ☐ PDGFRB break-apart — 5q32 rearrangement
- ☐ TRB break-apart — 7q34 rearrangement
- ☐ MYB/TRB — t(6;7)(q23;q34)
- ☐ TRB/TLX1 — t(7;10)(q34;q24)
- ☐ TRB/LMO1 — t(7;11)(q34;p15)
- ☐ TRB/LMO2 — t(7;11)(q34;p13)
- ☐ CDKN2A/D9Z1 — +9/9p-
- ☐ JAK2 break-apart — 9p24.1 rearrangement
- ☐ ABL1/BCR — t(9;22) or ABL1 amplification
- ☐ ABL1 break-apart — 9q34 rearrangement
- ☐ MLLT10/PICALM — t(10;11)
- ☐ MLL (KMT2A) break-apart — 11q23 rearrangement
- ☐ AFF1/MLL — t(4;11)(q21;q23)
- ☐ MLLT4(AFDN)/MLL — t(6;11)(q27;q23)
- ☐ MLLT3/MLL — t(9;11)(p22;q23)
- ☐ MLLT10/MLL — t(10;11)(p12;q23)
- ☐ MLL/ELL — t(11;19)(q23;p13.1)
- ☐ MLL/MLLT1 — t(11;19)(q23;p13.3)
- ☐ TRAD break-apart — 14q11.2 rearrangement
- ☐ MYC/TRAD — t(8;14)(q24.1;q11.2)
- ☐ TLX1/TRAD — t(10;14)(q24;q11.2)
- ☐ LMO1/TRAD — t(11;14)(p15;q11.2)
- ☐ LMO2/TRAD — t(11;14)(p13;q11.2)
- ☐ TP53/D17Z1 — -17/17p-
- ☐ TLBLF — T-Lymphoblastic Leukemia/Lymphoma, FISH, Tissue

For TLBLF: **must** specify probe sets to be performed.

- ☐ TAL1/STIL — 1p33 rearrangement
- ☐ TLX3/BCL11B — t(5;14)
- ☐ TRB break-apart — 7q34 rearrangement
- ☐ CDKN2A/D9Z1 — 9p-
- ☐ ABL1/BCR — t(9;22) or ABL1 amplification
- ☐ MLLT10/PICALM — t(10;11)
- ☐ MLL (KMT2A) break-apart — 11q23
- ☐ TRAD break-apart — 14q11.2 rearrangement
- ☐ TP53/D17Z1 — -17/17p-

## MYELOPROLIFERATIVE NEOPLASM (MPN)

### BCR/ABL1 Testing

**Diagnostic**

- ☐ BCRFX — BCR/ABL1 Qualitative Diagnostic Assay with Reflex to BCR/ABL1 p190 Quantitative Assay or BCR/ABL1 p210 Quantitative Assay
- ☐ BADX — BCR/ABL1, Qualitative, Diagnostic Assay***

**Monitoring**

- ☐ BCRAB — BCR/ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML)
- ☐ BA190 — BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay

**Additional**

- ☐ BAKDM — BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing

*** Algorithms are available online for these tests.
Visit www.MayoClinicLabs.com

## Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|---|---|
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

### JAK2-CALR-MPL-JAK2V671F Testing

- ☐ MPNR — Myeloproliferative Neoplasm, JAK2 V617F with Reflex to CALR and MPL
- ☐ PVJAK — Polycythemia Vera, JAK2 V617F with Reflex to JAK2 Exon 12-15, Sequencing for Erythrocytosis

JAK2 V617F Mutation Detection

- ☐ JAK2B — Blood***
- ☐ JAK2M — Bone Marrow***
- ☐ JAK2V — Varies

- ☐ CALR — CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN)***
- ☐ JAK2P — AK2P/JAK2 (9p24.1) Rearrangement, Hematologic Disorders, FISH, Tissue
- ☐ MPNCM — Myeloproliferative Neoplasm, CALR with Reflex to MPL
- ☐ MPLVS — MPL Exon 10 Mutation Detection

JAK2 Exon 12 and Other Non-V617F Mutation Detection

- ☐ JAKXB — Blood***
- ☐ JAKXM — Bone Marrow

### MISCELLANEOUS MYELOPROLIFERATIVE NEOPLASM (MPN)

- ☐ EOSDF — Chronic Eosinophilia, Diagnostic FISH
- ☐ EOSMF — Chronic Eosinophilia, Specified FISH

For EOSMF: **must** specify probe sets to be performed.

- ☐ FIP1LI, CHIC2, PDGFRA — 4q12 deletion or rearrangement
- ☐ PDGFRA — 4q12 rearrangement
- ☐ PDGFRB — 5q33 rearrangement
- ☐ PDGFRB/ETV6 — t(5;12)
- ☐ FGFR1 — 8p11.2 rearrangement
- ☐ JAK2 — 9p24.1 rearrangement
- ☐ ABL1 — 9q34 rearrangement
- ☐ BCR/ABL1 — t(9;22)

- ☐ MURA — Lysozyme (Muramidase), Plasma

### KIT Mutation Testing

- ☐ KITVS — KIT Asp816Val Mutation Analysis

### MYELOMA, AMYLOIDOSIS, & DYSPROTEINEMIA

#### Amyloid

- ☐ AMPIP — Amyloid Protein Identification, Paraffin, Mass Spectrometry
- ☐ TTRX — Amyloidosis, Transthyretin-Associated Familial, Reflex, Blood
- ☐ FMTT — Familial Variant, Targeted Testing
- ☐ TTRZ — TTR Gene, Full Gene Analysis

### Myeloma

Is patient on CD38 Therapy? ☐ Yes ☐ No

- ☐ FLCS — Immunoglobulin Free Light Chains
- ☐ MSMRT — Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report Bone Marrow
- ☐ NGPCM — MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing
- ☐ MRDMM — Multiple Myeloma Minimal Residual Disease by Flow, Bone Marrow
- ☐ MFCDF — Myeloma Fixed Cell, High Risk, FISH
- ☐ MSMRD — Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow
- ☐ QMPSS — Monoclonal Protein Study, Quantitative, Serum
- ☐ PBLI — Plasma Cell Assessment, Blood
- ☐ PCPRO — Plasma Cell DNA Content and Proliferation, Bone Marrow
- ☐ PCPDS — Plasma Cell Proliferative Disorder, FISH, Bone Marrow
- ☐ PLASF — Plasma Cell Proliferative Disorder, FISH, Tissue

*** Algorithms are available online for these tests.
Visit www.MayoClinicLabs.com



Print